CliffBio
small molecule

FOSFOMYCIN TROMETHAMINE

FOSFOMYCIN TROMETHAMINE

Loss of exclusivity—loss of exclusivity
CompanyAUCTA →See this company's full patent-cliff portfolio

Drug detail

Brand nameFOSFOMYCIN TROMETHAMINE
Active ingredientFOSFOMYCIN TROMETHAMINE
StrengthEQ 3GM BASE/PACKET
Dosage formFOR SOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalApril 2026
Marketing statusRX

More from AUCTA

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

FOSFOMYCIN TROMETHAMINE patent cliff — loss of exclusivity — | CliffBio